Wednesday, July 8, 2026

Patent intelligence · US

US 9695475

Competitive modulation of microRNAs

granted A61KA61K31/7088A61K31/7115A61K31/712
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 11
Applicant portfolio 222
Patent details — US 9695475
Jurisdiction
US
Status
granted
Grant date
Jul 4, 2017
Expiration
Jun 29, 2037
Claims
15
CPC classes
A61K, A61K31/7088, A61K31/7115, A61K31/712
View on Google Patents ↗

Quick answer

US 9695475 (Competitive modulation of microRNAs) is held by Ionis Pharmaceuticals, Inc.. Status: granted. Granted Jul 4, 2017. Expires Jun 29, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
15
CPC classes
A61K, A61K31/7088, A61K31/7115, A61K31/712, A61K31/7125, A61K31/713

More from Ionis Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12409188

    Modulators of HSD17B13 expression

    Ionis Pharmaceuticals, Inc. · Expires Sep 4, 2045

    granted
  2. US 12410225

    Modulation of dendritic cell lineages

    Orionis Biosciences, Inc · Expires Sep 4, 2045

    granted
  3. US 12410430

    Modulating apolipoprotein (A) expression

    Ionis Pharmaceuticals, Inc. · Expires Sep 4, 2045

    granted
  4. US 12364753

    CD8 binding agents

    Orionis Biosciences, Inc · Expires Jul 17, 2045

    granted
  5. US 12351633

    PD-1 and PD-L1 binding agents

    Orionis Biosciences, Inc · Expires Jul 3, 2045

    granted
  6. US 12350285

    Compounds and methods for reducing ATXN3 expression

    Ionis Pharmaceuticals, Inc. · Expires Jul 3, 2045

    granted
  7. US 12351614

    CLEC9A-based chimeric protein complexes

    Orionis Biosciences, Inc · Expires Jul 3, 2045

    granted
  8. US 12343357

    Compositions and methods for modulating MECP2 expression

    Ionis Pharmaceuticals, Inc. · Expires Jun 26, 2045

    granted

Frequently asked questions

What is US patent 9695475?

US 9695475 (Competitive modulation of microRNAs) is held by Ionis Pharmaceuticals, Inc.. Status: granted. Granted Jul 4, 2017. Expires Jun 29, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9695475?

Ionis Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 222 pharmaceutical patents for this assignee.

When does US 9695475 expire?

Our index shows an expiration date of Jun 29, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.